Are you thinking about switching from traditional cigarettes to e-cigarettes for the Great American Smokeout? Are you thinking that might be a better option than the traditional quit-smoking route? Think again.
For lung expert Brian Tiep, M.D., the dislike and distrust he feels for e-cigs comes down to this: The public has been burned by tobacco companies before.
The same companies that claimed cigarettes were safe, he says, now claim that electronic cigarettes – which aren’t regulated by the Food and Drug Administration – are safe.
“I was opened-minded initially,” said Tiep, a physician in pulmonary and critical care medicine at City of Hope. “Then the tobacco companies started buying out the e-cigarette companies. These products have no regulations whatsoever right now. You’re trusting them to do the right thing by you. They claimed tobacco was safe, and it turned out not to be.”
As for tobacco cigarettes, a recent study in the Journal of the American Medical Association tied smoking among U.S. adults to 14 million health conditions. Further, a U.S. District Court judge who in 2006 found tobacco companies guilty of lying to the public about the dangers of smoking, ordered the companies to admit their wrongdoing. The judge ruled they defrauded the public in five key ways: lying about the health damage caused by smoking, lying about the addictive nature of nicotine, marketing “low tar” and “light” cigarettes as healthier with no evidence that they are, deliberately making their products as addictive as possible and hiding the dangers of secondhand smoke. » Continue Reading
Hematologist Robert Chen, M.D., is boosting scientific discovery at City of Hope and, by extension, across the nation. Just ask the National Cancer Institute.
The institution recently awarded Chen the much-sought-after Clinical Investigator Team Leadership Award for boosting scientific discovery at City of Hope. He is one of just 11 researchers in the nation this year to receive the prestigious $100,000 grant from the NCI.
Fewer than 60 scientists have been granted the award since its inception five years ago.
The two-year NCI grant recognizes Chen’s exceptional merit as a clinical researcher whose innovative efforts are advancing therapies for lymphoma patients.
Chen, an assistant professor in the Department of Hematology & Hematopoietic Cell Transplantation, specializes in Hodgkin lymphoma research and treatment. His recent leadership of clinical trials testing the drug brentuximab vedotin helped clear its use for treating certain Hodgkin lymphoma patients who don’t respond well to stem cell transplantation. » Continue Reading
Great strides have been made in treating cancer – including lung cancer – but by the time people show symptoms of the disease, the cancer has usually advanced. That’s because, at early stages, lung cancer has no symptoms.
Only recently has lung cancer screening become an option. (Read more about the risks and benefits.) The U.S. Preventive Task Force recommends screening with low-dose computed tomography (more commonly called a low-dose CT scan) for individuals who meet the following guidelines:
- Age 55 to 80
– Have a 30 pack-year smoking history. That is, the person smoked a pack a day for 30 years, or two packs a day for 15 years.
– Currently smoke or quit within the last 15 years. » Continue Reading
Identifying cures for currently incurable diseases and providing patients with safe, fast and potentially lifesaving treatments is the focus of City of Hope’s new Alpha Clinic for Cell Therapy and Innovation (ACT-I).
The clinic is funded by an $8 million, five-year grant from the California Institute for Regenerative Medicine. The award is part of CIRM’s Alpha Stem Cell Clinics program, which aims to create one-stop centers for clinical trials focused on stem cell treatments for diseases.
Two trials were identified to launch the center, but additional trials are currently enrolling patients and will be part of this clinic. The first trials center on transplants of blood stem cells that have been modified to treat patients with AIDS and lymphoma, and on the use of neural stem cells – which naturally home to cancer cells – to deliver drugs directly to cancers hiding in the brain. Coming soon will be trials that use T cell immunotherapy, developed by researchers in City of Hope’s new Hematologic Malignancies and Stem Cell Transplantation Institute.
“We are committed to finding cures and treatments to diseases that are, for now, incurable,” said John Zaia, M.D., the Aaron D. Miller and Edith Miller Chair in Gene Therapy, chair of the Department of Virology and principal investigator for the stem cell clinic. “This grant recognizes City of Hope’s commitment to and leadership in this endeavor, as well as enables us to pursue the crucially important work of bringing the promising potential of stem cell treatments to fruition.” » Continue Reading
Cancer is a couple’s disease. It affects not just the person diagnosed, but his or her partner as well. It also affects the ability of both people to communicate effectively.
The Couples Coping with Cancer Together program at City of Hope teaches couples how to communicate and solve problems as a unit. Here are some practical behavior tips from that program:
Advice for the nonpatient:
• Actively encourage the sharing of emotional concerns and fears.
• Be open to her expression of concerns as often as she needs.
• Listen to her concerns without trying to “fix,” minimize or give advice (unless asked).
• Be physically present at all medical appointments, even when not asked.
• Talk with the breast cancer patient about how the illness is impacting you. » Continue Reading
Chemotherapy drugs work by either killing cancer cells or by stopping them from multiplying, that is, dividing. Some of the more powerful drugs used to treat cancer do their job by interfering with the cancer cells’ DNA and RNA growth, preventing them from copying themselves and dividing.
Such drugs, however, like Hydroxyurea, do have drawbacks. One is that the body metabolizes them quickly. Patients need frequent doses to achieve the desired effects. Because the side effects of the drugs are already considerable, increased use of them raises the risk of negative reactions. Another drawback is that cancer cells develop rapid resistance to the drugs, reducing their effectiveness.
A team effort
As a physician, molecular pharmacologist Yun Yen, M.D., Ph.D., knows well the limitations of chemotherapy drugs. He partnered with medicinal chemist David Horne, Ph.D., to find — and improve — a molecule, or compound, to overcome these problems.
First, Yen selected a promising anti-cancer compound from the National Cancer Institute’s library of anti-cancer agents. Then, using data obtained with the help of the skilled laboratory scientists in City of Hope’s Core (or “Shared”) Services, Horne began to make structural adjustments to improve the molecule’s effectiveness. Core Services provides researchers, specialized expertise, testing and instrumentation in fields such as molecular modeling, screening, medicinal chemistry and cancer biology. Access to these services enabled Yen and Horne to determine, even before preclinical testing, how the compound worked. » Continue Reading
During October, everything seems to turn pink – clothing, the NFL logo, tape dispensers, boxing gloves, blenders, soup cans, you name it – in order to raise awareness for what many believe is the most dangerous cancer that affects women: breast cancer. But, in addition to thinking pink, women should also think pearl. That color represents lung cancer.
Lung cancer is the No. 1 cancer killer of women, killing almost twice as many women as any other cancer. This year alone, it is estimated that lung cancer will claim the lives of 72,330 women.
When asked about the increasing rate of lung cancer in women, Karen Reckamp, M.D., M.S., co-director of the Lung Cancer and Thoracic Oncology Program at City of Hope, summed it up this way: “The main reason for the increase is due to smoking. The smoking trend began later among women, so we are now seeing the result. While there has been and overall lung cancer decline in the last decade, there are some places in the country, like the South, where rates for women are still increasing.”
But, Reckamp quickly points out that lung cancer is not just a smoker’s disease. Although smoking is the leading cause of lung cancer, other factors increase risk of the disease as well, such as exposure to radon, air pollution, even genetics. » Continue Reading
In February 2003, when she was only 16 months old, Maya Gallardo was diagnosed with acute myelogenous leukemia (AML) and, to make matters much worse, pneumonia.
The pneumonia complicated what was already destined to be grueling treatment regimen. To assess the extent of her illness, Maya had to endure a spinal tap procedure; the pneumonia meant it had to be done without anesthesia. Her parents could do nothing but watch, and try to comfort her.
The spinal tap revealed such severe leukemia that doctors at the children’s hospital where she was being treated said she would likely live only a few weeks.
Nonetheless, they stabilized her, and began treating her with chemotherapy. Normally, chemotherapy is not given to pneumonia patients, but because Maya’s leukemia was so advanced, she had no option but to undergo simultaneous treatment for both. If the chemotherapy went well, she would need a bone marrow transplant, the only option for curing her AML. » Continue Reading
Former smokers age 55 to 74 who rely on Medicare for health care services have just received a long-hoped-for announcement. Under a proposed decision from the Centers for Medicare and Medicaid Services, they’ll now have access to lung cancer screening with a low-dose CT scan.
The proposed decision, announced Monday, comes about seven months after a nonbinding panel shocked lung cancer doctors and experts nationwide by recommending against paying for the potentially lifesaving screening. The U.S. Preventive Services Task Force had already embraced such screening in the wake of the National Lung Screening Trial, which determined that the scans are effective in detecting early-stage lung cancer. Private plans were (and still are) expected to cover the screening beginning in 2015.
“I think it’s great Medicare is going to be covering lung cancer screening,” said Dan Raz, M.D., co-director of City of Hope’s Lung Cancer and Thoracic Oncology Program. “Lung cancer is such an important disease and education is so important to predicting death.”
While the Centers for Medicare and Medicaid Services (CMS) news is mostly good, it’s not without drawbacks. First, Medicare is covering people only up to age 74 – not age 80, as the U.S. Preventive Services Task Force recommended. Second, Medicare is mandating that all participating centers must submit data to a CMS-approved registry to get reimbursement – and there is no such registry right now. » Continue Reading
City of Hope has a longstanding commitment to combating diabetes, a leading national and global health threat. Already, it’s scored some successes, from research that led to the development of synthetic human insulin – still used by millions of patients – to potentially lifesaving islet cell transplants.
Diabetes researchers here continue to push forward in the fields of epigenetics, immunology, developmental biology, translational medicine, obesity, nutrition and metabolism. A pioneer in translational research for diabetes, City of Hope serves as the West Coast’s leading center for islet cell therapy, and is a leader in epigenetics and molecular research. Its diabetes program is built on a rich history that started with its founder, Rachmiel Levine, M.D. He was the first scientist to describe the role of insulin in regulating glucose entry into the cell. That work led to an understanding of what’s now known as “insulin resistance,” the hallmark of type 2 diabetes.
Diabetes comes in two basic types. Type 1 diabetes is usually diagnosed in children and young adults. In this disease, the body attacks its own pancreatic islet cells, which produce insulin, a hormone needed to convert sugar, starches and other food into energy the body needs. In type 2 diabetes, the body doesn’t use insulin properly, leading to blood sugar levels that are higher than normal – also called hyperglycemia. At first, the pancreas produces extra insulin to compensate, but over time it isn’t able to keep up and can’t maintain normal glucose levels.